Anticancer Drugs Practice Questions

Q: Which of the following drugs is widely used in the management of carcinoma of the breast?

Doxorubicin. **Explanation:** **Doxorubicin** (an Anthracycline antibiotic) is a cornerstone in the management of breast cancer. Its primary mechanism of action involves inhibiting **Topoisomerase II**, intercalating between DNA base pairs, and generating free radicals that cause DNA strand breaks. It is a key component of standard chemotherapy regimens such as **AC** (Adriamycin/Doxorubicin + Cyclophosphamide) and **FAC** (5-FU + Adriamycin + Cyclophosphamide). **Analysis of Incorrect Options:** * **Actinomycin–D (Dactinomycin):** Primarily used for pediatric solid tumors like **Wilms’ tumor**, Ewing’s sarcoma, and Rhabdomyosarcoma, as well as Gestational Choriocarcinoma. It is not a first-line agent for breast carcinoma. * **Bleomycin:** Known for causing pulmonary fibrosis, it is mainly used in **Germ cell tumors** (Testicular cancer), Hodgkin’s lymphoma, and squamous cell carcinomas of the head and neck. * **Dacarbazine:** An alkylating agent that is the drug of choice for **Malignant Melanoma** and is used in the ABVD regimen for Hodgkin’s Lymphoma. **High-Yield Clinical Pearls for NEET-PG:** * **Cardiotoxicity:** The most significant side effect of Doxorubicin is dose-dependent dilated cardiomyopathy. **Dexrazoxane** is an iron-chelating agent used to prevent this toxicity. * **Red Urine:** Doxorubicin can cause a harmless reddish discoloration of urine (not hematuria). * **Other Breast Cancer Drugs:** Remember that **Tamoxifen** (SERM) is used for ER/PR positive cases, and **Trastuzumab** is used for HER2/neu positive cases.

Q: Which of the following blocks DNA replication by getting incorporated into the DNA strand?

Cytarabine. **Explanation:** **Correct Option: A. Cytarabine** Cytarabine (Ara-C) is a pyrimidine analog (antimetabolite) that acts specifically during the **S-phase** of the cell cycle. Its mechanism involves two primary steps: 1. It is phosphorylated intracellularly into its active form, **cytarabine triphosphate**. 2. This active form competes with deoxycytidine triphosphate to be **incorporated into the DNA strand**. Once incorporated, it acts as a DNA chain terminator and inhibits **DNA polymerase**, thereby blocking DNA synthesis and repair. **Incorrect Options:** * **B & C (Nalidixic acid and Ciprofloxacin):** These are Quinolone/Fluoroquinolone antibiotics. They inhibit **DNA Gyrase** (Topoisomerase II) and **Topoisomerase IV** in bacteria. They do not get incorporated into the DNA strand. * **D (Paclitaxel):** This is a Taxane that acts on microtubules. It **stabilizes microtubules** by preventing depolymerization (freezing them in the polymerized state), leading to cell cycle arrest in the **M-phase**. **High-Yield Clinical Pearls for NEET-PG:** * **Drug of Choice:** Cytarabine is a cornerstone in the induction therapy of **Acute Myeloid Leukemia (AML)**. * **Specific Toxicity:** High-dose Cytarabine is associated with **Cerebellar toxicity** (ataxia, dysarthria) and **conjunctivitis** (prophylactic steroid drops are often used). * **Resistance:** Resistance to Cytarabine often occurs due to a decrease in the activating enzyme **deoxycytidine kinase**.

Q: Which of the following is the most emetogenic anticancer drug?

Cisplatin. **Explanation:** The emetogenicity of chemotherapy is categorized based on the percentage of patients who experience vomiting without antiemetic prophylaxis. **Cisplatin** is the prototype of **High Emetogenic Chemotherapy (HEC)**, with an emetic risk of >90%. **1. Why Cisplatin is the correct answer:** Cisplatin induces nausea and vomiting through two distinct pathways: * **Acute Phase (<24 hours):** Primarily due to the release of serotonin (5-HT) from enterochromaffin cells in the GI tract, stimulating 5-HT3 receptors. * **Delayed Phase (24–72 hours):** Primarily mediated by Substance P acting on Neurokinin-1 (NK1) receptors in the brainstem. Because it triggers both pathways intensely, it is considered the most emetogenic conventional agent. **2. Why the other options are incorrect:** * **Carboplatin:** While related to cisplatin, it is significantly less emetogenic (Moderate Emetogenic Risk, 30–90%) and has less renal and ototoxicity. * **High-dose Cyclophosphamide:** This is classified as HEC (especially >1500 mg/m²), but statistically, Cisplatin remains the gold standard for the highest emetic potential in clinical pharmacology. * **High-dose Methotrexate:** This is generally classified as having **Moderate to Low** emetogenic potential (30–60% risk). **3. Clinical Pearls for NEET-PG:** * **Drug of Choice for Cisplatin-induced vomiting:** A combination of a **5-HT3 antagonist** (e.g., Ondansetron), a **Corticosteroid** (Dexamethasone), and an **NK1 antagonist** (e.g., Aprepitant). * **Other HEC agents:** Dacarbazine, Mechlorethamine, and Streptozocin. * **Cisplatin Toxicity Profile:** Remember the mnemonic "3 Os" — **O**totoxicity, **O**ne (Nephrotoxicity), and **O**mited (Vomiting/Emesis). Amifostine is used to reduce cisplatin-induced nephrotoxicity.

Q: What is the primary toxicity of busulfan?

Severe myeloid suppression. **Explanation:**Busulfan is a bifunctional alkylating agent (alkyl sulfonate) primarily used in the treatment of Chronic Myeloid Leukemia (CML) and as a part of conditioning regimens prior to bone marrow transplantation [1].**Why Option B is Correct:**The hallmark and dose-limiting toxicity of busulfan is **severe and prolonged myeloid suppression** [1]. It specifically targets hematopoietic stem cells, leading to profound leucopenia, thrombocytopenia, and anemia. This property makes it highly effective for "ablating" the bone marrow before a transplant, but it requires careful monitoring to avoid irreversible marrow failure.**Analysis of Incorrect Options:** * **Option A (Lung Fibrosis):** While busulfan is famous for causing "Busulfan Lung" (interstitial pulmonary fibrosis), this is a chronic, dose-dependent side effect. In the context of "primary" or most common acute toxicity, myeloid suppression takes precedence.* **Option C (Cystitis):** Hemorrhagic cystitis is the classic toxicity associated with **Cyclophosphamide** and **Ifosfamide** due to the metabolite acrolein.* **Option D (Hyperuricemia):** This is a common feature of **Tumor Lysis Syndrome**, seen with many rapidly acting cytotoxic drugs (like Vincristine or Cytarabine), but it is not the specific primary toxicity defining busulfan's profile.**High-Yield Clinical Pearls for NEET-PG:** * **Skin Hyperpigmentation:** Busulfan often causes a characteristic "tan" or Addisonian-like skin darkening (without adrenal insufficiency).* **Seizures:** At high doses (conditioning regimens), busulfan can cross the blood-brain barrier and cause seizures; prophylactic **phenytoin** or benzodiazepines are often administered.* **Veno-occlusive disease (VOD):** Busulfan is a major risk factor for hepatic VOD (Sinusoidal Obstruction Syndrome).

Q: Which anti-cancer drug affects both DNA and RNA?

Actinomycin-D. **Explanation:** **Correct Answer: C. Actinomycin-D (Dactinomycin)** Actinomycin-D is an antitumor antibiotic derived from *Streptomyces*. Its primary mechanism of action involves **intercalating between guanine-cytosine (G-C) base pairs** of the DNA double helix. This physical binding creates a stable complex that inhibits the enzyme **DNA-dependent RNA polymerase**, thereby blocking the synthesis of messenger RNA (mRNA). At higher concentrations, it also inhibits **DNA polymerase**, leading to the inhibition of DNA replication. Because it disrupts both the template function (DNA replication) and the transcription process (RNA synthesis), it is the correct choice. **Analysis of Incorrect Options:** * **A. 5-Fluorouracil (5-FU):** An antimetabolite (pyrimidine analog) that primarily inhibits **thymidylate synthase**, leading to "thymineless death" of DNA. While it can be incorporated into RNA, its hallmark action is DNA synthesis inhibition. * **B. Methotrexate:** A folate antagonist that inhibits **dihydrofolate reductase (DHFR)**. This depletes tetrahydrofolate, which is essential for purine and thymidylate synthesis, primarily affecting DNA synthesis. * **C. Etoposide:** A plant alkaloid that acts specifically by inhibiting **Topoisomerase II**, leading to DNA strand breaks. It does not directly affect RNA synthesis. **High-Yield NEET-PG Pearls:** * **Clinical Use:** Actinomycin-D is a component of the "VAC" regimen used for **Wilms’ tumor** and **Rhabdomyosarcoma**. It is also highly effective in **Gestational Choriocarcinoma**. * **Toxicity:** It is a potent vesicant (causes tissue necrosis on extravasation) and causes significant bone marrow suppression. * **Cell Cycle:** It is cell-cycle non-specific but most active in the G1 phase.

Q: Cisplatin is known to cause several adverse effects. Which of the following is NOT a typical side effect of cisplatin therapy?

Cardiomyopathy. **Explanation:** **Cisplatin** is a potent platinum-based alkylating agent used for various solid tumors. The correct answer is **Cardiomyopathy**, as this is not a characteristic side effect of Cisplatin. Instead, cardiomyopathy is the classic dose-limiting toxicity associated with **Anthracyclines** (e.g., Doxorubicin and Daunorubicin). **Analysis of Options:** * **Nephrotoxicity (Option B):** This is the most significant dose-limiting toxicity of Cisplatin [1]. It causes acute tubular necrosis. It is managed with aggressive **Amifostine** (a cytoprotective agent) and vigorous hydration with chloride diuresis [1]. * **Neuropathy (Option C):** Cisplatin frequently causes a sensory peripheral neuropathy (stocking-glove pattern) due to its accumulation in the dorsal root ganglia [1]. * **Tinnitus/Ototoxicity (Option D):** Cisplatin is highly ototoxic, leading to high-frequency hearing loss and tinnitus [1]. This is often irreversible and more common in the pediatric population. **High-Yield Clinical Pearls for NEET-PG:** 1. **Mnemonic for Cisplatin Toxicity:** Remember the **"3 Ns"** — **N**ephrotoxicity, **N**eurotoxicity, and **N**ausea/vomiting (it is highly emetogenic) [1]. 2. **Ototoxicity:** Unlike many other drugs, Cisplatin-induced hearing loss is bilateral and permanent [1]. 3. **Electrolyte Imbalance:** It characteristically causes **Hypomagnesemia** and hypokalemia due to renal tubular damage. 4. **Carboplatin:** A related drug that is less nephrotoxic and ototoxic but causes significant **Myelosuppression** (thrombocytopenia) [1].

Q: Arsenic is used in the treatment of which condition?

Acute promyelocytic leukemia. **Explanation:** **Arsenic Trioxide ($As_2O_3$)** is a highly effective agent specifically used for **Acute Promyelocytic Leukemia (APL)**, which is the M3 subtype of Acute Myeloid Leukemia. **Why Option A is Correct:** APL is characterized by a specific chromosomal translocation **t(15;17)**, which creates the **PML-RARα** fusion protein. This protein blocks myeloid differentiation at the promyelocyte stage. Arsenic trioxide works by binding to the PML moiety, inducing the degradation of the fusion protein and promoting apoptosis of the leukemic cells. It is currently the standard of care for both newly diagnosed and relapsed APL, often used in combination with **All-Trans Retinoic Acid (ATRA)**. **Why Other Options are Incorrect:** * **B. Acute Lymphoblastic Leukemia (ALL):** Treated primarily with vincristine, corticosteroids, L-asparaginase, and anthracyclines. Arsenic has no established role here. * **C. Chronic Myeloid Leukemia (CML):** The mainstay of treatment is Tyrosine Kinase Inhibitors (TKIs) like **Imatinib**, which target the BCR-ABL fusion protein. * **D. Transient Myeloproliferative Disorder (TMD):** This is a self-limiting condition seen in neonates with Down Syndrome. It usually resolves spontaneously and does not require arsenic therapy. **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism:** Degradation of PML-RARα fusion protein and induction of differentiation. * **Side Effects:** The most characteristic side effect is **QT interval prolongation** (requires ECG monitoring). It can also cause **Differentiation Syndrome** (fever, dyspnea, weight gain), treated with dexamethasone. * **Historical Context:** Arsenic was historically a component of **Fowler’s solution**, used for various ailments before modern chemotherapy.

Q: Which of the following are alkylating agents?

Chlorambucil. **Explanation:** **Alkylating agents** are cell-cycle non-specific drugs that act by forming reactive carbonium ions, which create covalent bonds with DNA (primarily at the N7 position of Guanine). This leads to DNA cross-linking, strand breakage, and inhibition of replication. * **Chlorambucil (Option B):** This is a nitrogen mustard derivative and a classic example of an alkylating agent. It is primarily used in the treatment of Chronic Lymphocytic Leukemia (CLL). * **Busulfan (Option D):** While Busulfan is also an alkylating agent (an alkyl sulfonate), the question asks to identify "the" correct option among the choices provided. In many standard MCQ formats, Chlorambucil is the primary representative of the nitrogen mustard class often tested. *(Note: In a multiple-response scenario, both B and D are alkylating agents; however, Chlorambucil is the most definitive answer for nitrogen mustards).* **Why other options are incorrect:** * **Doxorubicin (Option A):** An **Antitumor Antibiotic** (Anthracycline). It works by inhibiting Topoisomerase II, intercalating between DNA base pairs, and generating free radicals. * **Vinblastine (Option C):** A **Vinca Alkaloid** (Anti-microtubule agent). It inhibits tubulin polymerization, leading to mitotic arrest in the M-phase. **High-Yield Clinical Pearls for NEET-PG:** 1. **Cyclophosphamide:** The most widely used alkylating agent; causes **hemorrhagic cystitis** (prevented by **MESNA** and hydration). 2. **Busulfan:** Specifically associated with **pulmonary fibrosis** ("Busulfan lung") and skin hyperpigmentation. 3. **Nitrosoureas (Lomustine, Carmustine):** Alkylating agents with high lipid solubility, making them the drugs of choice for **brain tumors**. 4. **Dacarbazine:** An alkylating agent used in the ABVD regimen for Hodgkin’s Lymphoma.

Q: Aromatase inhibitors are used in the treatment of which of the following cancers?

Breast cancer. **Explanation:** **Aromatase inhibitors (AIs)**, such as Letrozole, Anastrozole, and Exemestane, are the treatment of choice for hormone receptor-positive (ER/PR+) **breast cancer** in postmenopausal women. The underlying medical concept involves the synthesis of estrogen. In postmenopausal women, the ovaries stop producing estrogen; instead, the enzyme **aromatase** converts adrenal androgens (androstenedione and testosterone) into estrogens (estrone and estradiol) in peripheral tissues like fat and muscle. Since many breast tumors are estrogen-dependent, inhibiting this enzyme deprives the tumor cells of the growth signals they need, leading to tumor regression. **Analysis of Incorrect Options:** * **A. Lung Cancer:** Primarily treated with surgery, radiotherapy, and chemotherapy (e.g., Cisplatin) or targeted therapies (e.g., EGFR inhibitors like Erlotinib), but not hormonal manipulation via aromatase. * **C. Liver Cancer (HCC):** Management involves surgical resection, kinase inhibitors (e.g., Sorafenib), or transplant; it is not driven by estrogen pathways. * **D. Colon Cancer:** Standard treatment involves the FOLFOX regimen (5-Fluorouracil, Leucovorin, Oxaliplatin). It does not respond to aromatase inhibition. **High-Yield Clinical Pearls for NEET-PG:** * **Drug of Choice:** AIs are preferred over Tamoxifen in **postmenopausal** women because they are more effective and lack the risk of endometrial cancer. * **Tamoxifen vs. AIs:** Tamoxifen is a SERM used in **premenopausal** women. AIs are ineffective in premenopausal women because they cannot overcome the high estrogen production from functional ovaries. * **Side Effects:** The most characteristic side effect of AIs is **osteoporosis** and increased risk of fractures (due to total estrogen deprivation), whereas Tamoxifen increases the risk of **thromboembolism** and **endometrial carcinoma**.

Question 1

Which of the following drugs is widely used in the management of carcinoma of the breast?

Accepted Answer

Doxorubicin

Answer

Actinomycin–D

Answer

Bleomycin

Answer

Dacarbazine

Question 2

Which of the following blocks DNA replication by getting incorporated into the DNA strand?

Accepted Answer

Cytarabine

Answer

Nalidixic acid

Answer

Ciprofloxacin

Answer

Paclitaxel

Question 3

Fulvestrant is used in the treatment of which of the following conditions?

Accepted Answer

HR positive metastatic breast cancer in postmenopausal women

Answer

Male breast cancer

Answer

Paget's disease

Answer

Acute myeloid leukemia associated with Down's syndrome

Question 4

Which of the following is the most emetogenic anticancer drug?

Accepted Answer

Cisplatin

Answer

Carboplatin

Answer

High dose cyclophosphamide

Answer

High dose methotrexate

Question 5

What is the primary toxicity of busulfan?

Accepted Answer

Severe myeloid suppression

Answer

Lung fibrosis

Answer

Cystitis

Answer

Hyperuricemia

Question 6

Which anti-cancer drug affects both DNA and RNA?

Accepted Answer

Actinomycin-D

Answer

5-Fluorouracil

Answer

Methotrexate

Answer

Etoposide

Question 7

Cisplatin is known to cause several adverse effects. Which of the following is NOT a typical side effect of cisplatin therapy?

Accepted Answer

Cardiomyopathy

Answer

Nephrotoxicity

Answer

Neuropathy

Answer

Tinnitus

Question 8

Arsenic is used in the treatment of which condition?

Accepted Answer

Acute promyelocytic leukemia

Answer

Acute lymphoblastic leukemia

Answer

Chronic myeloid leukemia

Answer

Transient myeloproliferative disorder

Question 9

Which of the following are alkylating agents?

Accepted Answer

Chlorambucil

Answer

Doxorubicin

Answer

Vinblastine

Answer

Busulfan

Question 10

Aromatase inhibitors are used in the treatment of which of the following cancers?

Accepted Answer

Breast cancer

Answer

Lung cancer

Answer

Liver cancer

Answer

Colon cancer

Anticancer Drugs — MCQs

Anticancer Drugs — MCQs

On this page

Practice by Chapter

Want unlimited practice?